Table of Contents
More than 3.1 million women in U.S are either suffering from breast cancer or have a history. A woman’s risk of developing breast cancer in a lifetime is about 1 in 8, whereas it is 1 in 1000 in the case of men. Following new cases of breast cancer are estimated to appear in the year 2017:
- New cases of breast cancer – 252,710
- New cases of invasive breast cancer in men – 2,470
In 2017, about 30% of the diagnosed cancer cases in women are expected to be breast cancer. The mortality risk due to breast cancer is higher in African-American women as compared to Asian, Native-American women, and Hispanic women.
Breast cancer screening tests include the following:
- Breast examination
- Self-examination (generally discouraged)
- Clinical examination (cannot replace Mammography)
- Mammography (Most proven in reducing breast cancer mortality)
American Cancer Society (ACS) Guidelines
Following are the ACS guidelines for the screening of breast cancer:
- Screening with mammography is strongly recommended in women who are at the age of 45.
- Annual screening in the age groups of 45-54 years.
- Biennial screening in women who are 55 years or older.
- Screening should be continued for as long as the individual is in good health and has a life expectancy of at least 10 years.
US Preventive Services Task Force (USPSTF) screening guidelines:
- There is no need for the clinicians to teach women breast self-examination.
- There is insufficient data to state the additional benefits or harms of clinical breast examination in the presence of mammographic screening for women who are aged 40 or older.
Recommendations for screening mammography are as follows:
- Women aged 40-49 years should NOT be offered screening mammography. Biennial screening mammography decision before 50 years of age should be an individual one. In this case, the values of a patient regarding specific benefit and harms should be taken into account before screening mammography.
- Screening mammography should be offered every two years to women between the age group of 50 to 74.
- There is insufficient data to state the additional benefits and drawbacks of screening mammography for women who are aged 75 or older.
- Currently, there is insufficient evidence on whether or not digital breast tomosynthesis (DBT) has any additional advantages or disadvantages when used as a priority screening method for breast cancer.
The American Congress of Obstetricians and Gynecologists (ACOG) Screening guidelines
The ACOG guidelines for breast cancer screening are as follows:
Encourage breast self-awareness and breast self-examination. Any changes in the breasts should be reported to the healthcare provider.
- Clinical breast examinations for women of the age group 20-39 are recommended every 1 to 3 years.
- Clinical breast examinations for women of the age group 40 and above are recommended on an annual basis.
It is important to educate women on the predictive values of mammographic screening for breast cancer detection. The potential for false positive and false negative screening should be clearly communicated to the patient. The women receiving mammogram should be informed that there is a potential for additional imaging or biopsies that might be required based on results of mammography.
- All women who are 40 years or older should have annual mammographic screening.
- Based on individual risk and concerns, biennial screening can be recommended to the women who do not accept annual screening.
- Women who are at an average risk of breast cancer development should NOT be offered breast magnetic resonance imaging (MRI).
- Women who have positive test results for BRCA1and BRCA2 gene mutations should be offered enhanced screening. Risk reduction methods should also be discussed with the individuals.
- Enhanced screening can be provided to those women who are either untested or have negative test results for BRCA1and BRCA2 gene mutations in addition to high risk (20 percent or greater) for breast cancer.